Investor Presentation - First Six Months of 2021

42 Investor presentation First six months of 2021 Novo Nordisk global insulin market leadership expanded to 47.3% and the global insulin volume market grew by 2.2% North America Operations Market growth: -0.3% MS: 39.2% MS gain/loss¹: -0.5%-p Sales growth: -11% Global Market growth: 1.6% MS: 47.3% MS gain/loss¹: 0.3%-p Sales growth: 1% International Operations Market growth: 2.4% MS: 50.3% MS gain/loss: 0.6%-p Sales growth: 6% USA Market growth: -0.4% MS: 38.9% MS gain/loss: -0.8%-p Sales growth: -11% Source: IQVIA MAT, May 2021 volume figures Note: Sales growth for first six months of 2021 at constant exchange rates; Market shares are for Novo Nordisk and market growth for the total insulin market 1MS gain/loss compared with May 2020 reported MS EMEA: Europe, Middle East and Africa; MS: Market share; RoW: Asia Pacific; Latin America EMEA Market growth: 0.0% MS: 47.6% MS gain/loss: 0.5%-p Sales growth: 2% ROW Market growth: 5.9% MS: 57.2% MS gain/loss: 0.3%-p Sales growth: 10% Region China Market growth: 6.4% MS: 50.8% MS gain/loss: 0.4%-p Sales growth: 10% Novo NordiskⓇ

View entire presentation